CA2447732A1 - Antineoplastic combinations - Google Patents

Antineoplastic combinations Download PDF

Info

Publication number
CA2447732A1
CA2447732A1 CA002447732A CA2447732A CA2447732A1 CA 2447732 A1 CA2447732 A1 CA 2447732A1 CA 002447732 A CA002447732 A CA 002447732A CA 2447732 A CA2447732 A CA 2447732A CA 2447732 A1 CA2447732 A1 CA 2447732A1
Authority
CA
Canada
Prior art keywords
cancer
neoplasm
rapamycin
mtor inhibitor
alkylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002447732A
Other languages
English (en)
French (fr)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2447732A1 publication Critical patent/CA2447732A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002447732A 2001-06-01 2002-05-29 Antineoplastic combinations Abandoned CA2447732A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
US60/295,190 2001-06-01
US60/295,236 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
CA2447732A1 true CA2447732A1 (en) 2002-12-12

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002447732A Abandoned CA2447732A1 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Country Status (17)

Country Link
EP (1) EP1392286A2 (pl)
JP (1) JP2004532883A (pl)
KR (1) KR100875611B1 (pl)
CN (1) CN100496485C (pl)
AU (2) AU2002259309B2 (pl)
BR (1) BR0210101A (pl)
CA (1) CA2447732A1 (pl)
CO (1) CO5540294A2 (pl)
EA (1) EA007530B1 (pl)
HU (1) HUP0400006A2 (pl)
IL (1) IL158800A0 (pl)
MX (1) MXPA03010907A (pl)
NO (1) NO20035317L (pl)
NZ (1) NZ529877A (pl)
PL (1) PL367267A1 (pl)
SG (1) SG153647A1 (pl)
WO (1) WO2002098416A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3143995T3 (en) 2001-02-19 2019-01-28 Novartis Pharma Ag Rapamycin derivative for the treatment of lung cancer
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
EP3488866A1 (en) * 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
DK2275103T3 (da) * 2005-11-21 2014-07-07 Novartis Ag mTor-inhibitorer ved behandling af endokrine tumorer
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
EP2004163B1 (en) * 2006-04-05 2014-09-17 Novartis Pharma AG Combination of everolimus and vinorelbine
PT2131821T (pt) * 2007-03-07 2018-10-10 Abraxis Bioscience Llc Nanopartícula que compreende rapamicina e albumina como agente anticancerígeno
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20090312360A1 (en) 2008-06-17 2009-12-17 Wyeth Antineoplastic Combinations Containing HKI-272 and Vinorelbine
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
CA2755789C (en) 2009-04-06 2016-01-19 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
SG43072A1 (en) * 1991-06-18 1997-10-17 American Home Prod Method of treating adult t-cell leukemia/lymphoma
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DK3143995T3 (en) * 2001-02-19 2019-01-28 Novartis Pharma Ag Rapamycin derivative for the treatment of lung cancer

Also Published As

Publication number Publication date
EA200301319A1 (ru) 2004-04-29
JP2004532883A (ja) 2004-10-28
KR100875611B1 (ko) 2008-12-24
PL367267A1 (pl) 2005-02-21
AU2002259309B2 (en) 2008-05-01
EP1392286A2 (en) 2004-03-03
CO5540294A2 (es) 2005-07-29
IL158800A0 (en) 2004-05-12
KR20040025923A (ko) 2004-03-26
EA007530B1 (ru) 2006-10-27
AU2008202690A1 (en) 2008-07-10
BR0210101A (pt) 2004-06-08
CN100496485C (zh) 2009-06-10
MXPA03010907A (es) 2004-02-17
NO20035317L (no) 2003-12-22
WO2002098416A2 (en) 2002-12-12
SG153647A1 (en) 2009-07-29
NZ529877A (en) 2006-08-31
HUP0400006A2 (hu) 2004-04-28
WO2002098416A3 (en) 2003-03-13
NO20035317D0 (no) 2003-11-28
CN1646120A (zh) 2005-07-27

Similar Documents

Publication Publication Date Title
US20030008923A1 (en) Antineoplastic combinations
US20060030547A1 (en) Antineoplastic combinations
AU2008202690A1 (en) Antineoplastic combination
EP1385551B1 (en) Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
JP6522056B2 (ja) ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
US20070105887A1 (en) Antineoplastic combinations of temsirolimus and sunitinib malate
US20060035904A1 (en) Antineoplastic combinations
US20050187184A1 (en) Antineoplastic combinations
ZA200304603B (en) Use of CCI-799 as an antineoplastic agent.
AU2002259309A1 (en) Antineoplastic combinations
AU2020201862A1 (en) Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
AU2013204788B2 (en) Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2002227313B2 (en) Use of CCI-779 as an antineoplastic agent
AU2002257123A1 (en) Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
AU2002227313A1 (en) Use of CCI-779 as an antineoplastic agent

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued